Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q13363
UPID:
CTBP1_HUMAN
Alternative names:
-
Alternative UPACC:
Q13363; Q4W5N3; Q7Z2Q5
Background:
C-terminal-binding protein 1 plays a pivotal role in various cellular processes, including acting as a corepressor for transcription regulators like GLIS2 or BCL6. It exhibits dehydrogenase activity and is crucial in maintaining the balance between tubular and stacked structures in the Golgi complex. Additionally, it is instrumental in the differentiation of brown adipose tissue (BAT).
Therapeutic significance:
The protein is linked to Hypotonia, ataxia, developmental delay, and tooth enamel defect syndrome, an autosomal dominant disorder. This association highlights its potential as a target for therapeutic intervention in treating or managing this syndrome.